
|Slideshows|February 25, 2015
Interleukin Inhibitors in Brief
Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.
Advertisement
Advertisement
















